IP Verse

Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains - EP3228315

The patent EP3228315 was granted to Amgen Research Munich on Nov 25, 2020. The application was originally filed on Oct 27, 2011 under application number EP17159560A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3228315

AMGEN RESEARCH MUNICH
Application Number
EP17159560A
Filing Date
Oct 27, 2011
Status
Granted And Under Opposition
Oct 23, 2020
Grant Date
Nov 25, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

F HOFFMANN LA ROCHEAug 24, 2021MEWBURN ELLIS -
JAMES POOLEAug 24, 2021CARPMAELS & RANSFORD -

Patent Citations (23) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2010EP66207-
DESCRIPTIONEP0623679
DESCRIPTIONWO2004106381
DESCRIPTIONWO2007068354
DESCRIPTIONWO2008119565
DESCRIPTIONWO2008119566
DESCRIPTIONWO2008119567
DESCRIPTIONWO9954440
EXAMINATIONWO2008119567
EXAMINATIONWO2011051307
OPPOSITIONEP3228315
OPPOSITIONUS2007224191
OPPOSITIONWO2006114115
OPPOSITIONWO2007068354
OPPOSITIONWO2009070642
OPPOSITIONWO2011051307
OPPOSITIONWO2012055961
OPPOSITIONWO2012062596
OPPOSITIONWO9954440
OTHERWO2011051307
SEARCHWO2007068354
SEARCHWO2012055961
SEARCHWO9954440

Non-Patent Literature (NPL) Citations (46) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BARGOU ET AL., SCIENCE, (2008), vol. 321, pages 974 - 977-
DESCRIPTION- CHESON ET AL., J CLIN ONCOL., (199904), vol. 17, no. 4, page 1244-
DESCRIPTION- CRICK, J MOL BIOL, (1966), vol. 19, pages 548 - 555-
DESCRIPTION- HOSSE ET AL., PROTEIN SCI., (2006), vol. 15, pages 14 - 27-
DESCRIPTION- MOLNAR; LAPIN; GOOTHUIS, NEUROONCOL, (1995), vol. 25, no. 1, pages 19 - 28-
DESCRIPTION- NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, pages 443 - 453-
DESCRIPTION- NICAISE ET AL., PROTEIN SCI., (2004), vol. 13, pages 1882 - 1891-
DESCRIPTION- NYGREN; UHLEN, CURR. OPIN. STRUC. BIOL, (1997), vol. 7, pages 463 - 469-
DESCRIPTION- SKERRA, CURR. OPIN. BIOTECHNOL., (2005), vol. 18, pages 295 - 304-
DESCRIPTION- SMITH; WATERMAN, ADV. APPL. MATH, (1981), vol. 2, pages 482 - 489-
EXAMINATION- Anonymous, "Encephalopathy - Wikipedia", (20190209), URL: https://en.wikipedia.org/wiki/Encephalopathy-
EXAMINATION- Anonymous, "Muromonab-CD3 - Wikipedia", (20180123), URL: https://en.wikipedia.org/wiki/Muromonab-CD3, (20190604), XP055593752-
EXAMINATION- GUARINO M ET AL, "EFNS guidelines on management of neurological problems in liver transplantation", EUROPEAN JOURNAL OF NEUROLOGY, (200601), vol. 13, no. 1, ISSN 1351-5101, pages 2 - 9-
EXAMINATION- STONE J ET AL, "Functional weakness and sensory disturbance", JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, (200209), vol. 73, no. 3, ISSN 0022-3050, pages 241 - 245-
OPPOSITION- Anonymous, "Micromet ASH Update", Micromet Presentation, (20101207), pages 1 - 28, Micromet Presentation, (20161004), XP055307533-
OPPOSITION- BARGOU et al., "Supporting Online Material for Tumor Regression in Cancer Patients by Very Low Doses of a T CellEngaging Antibody", SCIENCE, (20080000), XP055866805-
OPPOSITION- BARGOU RALF, ET AL, "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.", Science, US , (20080815), vol. 321, no. 5891, ISSN 0036-8075, pages 974 - 977, XP002572417-
OPPOSITION- CHATENOUD et al., "CORTICOSTEROID INHIBITION OF THE OKT3-INDUCEDCYTOKINE-RELATED SYNDROME—DOSAGE AND KINETICSPREREQUISITES", Transplantation, (19910000), vol. 51, pages 334 - 338, XP055866709-
OPPOSITION- Chatenoud L., Et Al, "Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites", TRANSPLANTATION, (19910201), vol. 51, no. 2, pages 334 - 338, XP055439988-
OPPOSITION- FRIEND et al., "PHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION", Transplantation, (19990000), vol. 68, no. Issue 11, page 1632, XP0009011271-
OPPOSITION- GOEBELER et al., "CD3/CD19 BISPECIFIC BITE® ANTIBODY BLINATUMOMAB TREATMENT OF NON-HODGKIN LYMPHOMA (NHL) PATIENTS: 60 pG/M2/DBY CONTINUOUS INFUSION IS TOLERABLE AND RESULTS IN DURABLE RESPONSES", Haematologica, (20100000), vol. 95, no. s2, XP055866700-
OPPOSITION- Goebeler, "Haematologica. Abstract 0559", (20100601), vol. 95, no. s2, pages 230 - 230, XP055864759-
OPPOSITION- KLINGER, "Wirkmechanismus des bispezifischen anti- CD 19 x onti- CD 3 BiTE- Antikorpers MT103 in Patienten mit rezidivem indolenten B-Zell-Non-Hodgkin-Lymphom", Dissertation, Tubingen, (20090000), XP055541894-
OPPOSITION- PECES et al., "High-Dose MethylprednisoloneInhibits the 0KT3-induced Cytokine-Related Syndrome", Nephron, (19930000), vol. 63, page 118, XP055866713-
OPPOSITION- SHIH et al., "ROLE OF CORTICOSTEROIDS IN PALLIATIVE CARE", J. Pain and Palliative Care Pharmacology, (20090000), vol. 21, no. 4, pages 69 - 76, XP055443261-
OPPOSITION- TEN BERGE et al., "Guidelines for the Optimal Use of Muromonab CD3 in Transplantation", Biodrugs, Apr., (19990000), vol. 11, no. 4, XP0008185106-
OPPOSITION- Walsh Declan, Avashia Jay, "Glucocorticoids in clinical oncology", Cleveland Clinical Journal of Medicine, (19920901), vol. 59, pages 505 - 515, XP055864752-
OPPOSITION- YURASZECK et al., "Translation and Clinical Development of Bispecific T-cell Engaging Antibodies forCancer Treatment", Clinical Pharmacology & Therapeutics, (20170000), vol. 101, no. 5, XP055866812-
OPPOSITION- HOFFMANN et al., "Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct", Int. J. Cancer, (20050000), vol. 115, pages 98 - 104, XP002335808
OPPOSITION- SCHLERETH et al., "T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct", Cancer Immunol. Immunother., (20060000), vol. 55, pages 503 - 514, XP019333227
OPPOSITION- Christian Brandl ; Cornelia Haas ; Sandrine d’Argouges ; Tanja Fisch ; Peter Kufer ; Klaus Brischwein ; Nadja Prang ; Ralf Bargou ; JoAnn Suzich ; Patrick A. Baeuerle ; Robert Hofmeister, "The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct", Cancer Immunology, Immunotherapy, Berlin, DE , (20070220), vol. 56, no. 10, doi:10.1007/s00262-007-0298-z, ISSN 1432-0851, pages 1551 - 1563, XP019539092
OPPOSITION- Christian Brandl ; Cornelia Haas ; Sandrine d’Argouges ; Tanja Fisch ; Peter Kufer ; Klaus Brischwein ; Nadja Prang ; Ralf Bargou ; JoAnn Suzich ; Patrick A. Baeuerle ; Robert Hofmeister, "The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct", Cancer Immunology, Immunotherapy, Springer, Berlin, DE, Berlin, DE , (20070220), vol. 56, no. 10, doi:10.1007/s00262-007-0298-z, ISSN 1432-0851, pages 1551 - 1563, XP019539092
OPPOSITION- Todd D. Rozen, "Migraine headache: Immunosuppressant therapy", Current Treatment Options in Neurology, Springer US, New York, New York, (20020901), vol. 4, no. 5, doi:10.1007/s11940-002-0050-0, ISSN 1092-8480, pages 395 - 401, XP055439993
OPPOSITION- M Guarino, Et Al, "EFNS guidelines on management of neurological problems in liver transplantation", EUROPEAN JOURNAL OF NEUROLOGY, RAPID SCIENCE PUBLISHERS., GB, GB , (20060112), vol. 13, no. 1, doi:10.1111/j.1468-1331.2006.01353.x, ISSN 1351-5101, pages 2 - 9, XP055439997
OPPOSITION- BARGOU et al., "TUMOR REGRESSION IN CANCER PATIENTS BY VERY LOW DOSES OF AA T CELL-ENGAGING ANTIBODY", Science, (20080000), vol. 321, page 974, XP055626096
OPPOSITION- BENJAMIN et al., "The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia", Therapeutic advances in Hematology, (20160000), vol. 7, no. 3, pages 142 - 156, XP055443264
OPPOSITION- BRESLIN, "Cytokine-Release Syndrome Overview and Nursing Implications", Clinical J. Oncology Nursing, (20070000), vol. 11, no. 1, page 37, XP055440000
OPPOSITION- Baeuerle P A, Reinhardt C, Kufer P, "BiTE: a new class of antibodies that recruit T-cells", Drugs of the Future, ES , (20080101), vol. 33, no. 2, doi:10.1358/DOF.2008.033.02.1172578, ISSN 0377-8282, pages 137 - 147, XP002667644
OPPOSITION- Rossi Stephen, Schroeder Timothy, Hariharan Sundaram, First, "Prevention and Management of the Adverse Effects Associated with Immunosuppressive Therapy", DRUG SAFETY., NZ , (19930801), vol. 9, no. 2, doi:10.2165/00002018-199309020-00004, ISSN 0114-5916, pages 104 - 131, XP009516829
OTHER- Anonymous, "Encephalopathy, Wikipedia", (20190209), pages 1 - 6, URL: https://en.wikipedia.org/w/index.php?title=Encephalopathy&oldid=882530345, XP055599393-
OTHER- Anonymous, "Muromonab-CD3, Wikipedia", (20180123), URL: https://en.wikipedia.org/wiki/Muromonab-CD3, XP055593752-
OTHER- M. Guarino, "EFNS guidelines on management of neurological problems in liver transplantation", EUROPEAN JOURNAL OF NEUROLOGY, (20060112), vol. 13, no. 1, pages 2 - 9, XP055439997
SEARCH- GOEBELER M ET AL, "CD3/CD19 BISPECIFIC BITE (R) ANTIBODY BLINATUMOMAB TREATMENT OF NON-HODGKIN LYMPHOMA (NHL) PATIENTS: 60 mu G/M-2/D BY CONTINUOUS INFUSION IS TOLERABLE AND RESULTS IN DURABLE RESPONSES", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, FONDAZIONE FERRATA STORTI, IT, (20100610), vol. 95, no. Suppl. 2, ISSN 0390-6078, page 230URL, XP002667641 [Y] 1,3-16 * abstract *-
SEARCH- CHRISTIAN BRANDL ET AL, "The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20070220), vol. 56, no. 10, doi:10.1007/S00262-007-0298-Z, ISSN 1432-0851, pages 1551 - 1563, XP019539092 [Y] 1-16 * abstract * * page 1552, column 1, paragraph l - column 2, paragraph 2 *
SEARCH- FRIEND P J ET AL, "PHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION", TRANSPLANTA, WILLIAMS AND WILKINS, GB, (19991215), vol. 68, no. 11, doi:10.1097/00007890-199912150-00005, ISSN 0041-1337, pages 1632 - 1637, XP009011271 [X] 1,15 * abstract * * page 1635, column 1, line 7 - line 9 * [Y] 1-16
SEARCH- TEN BERGE I J ET AL, "Guidelines for the optimal use of muromonab CD3 in transplantation.", BIODRUGS : CLINICAL IMMUNOTHERAPEUTICS, BIOPHARMACEUTICALS AND GENE THERAPY APR 1999, (199904), vol. 11, no. 4, ISSN 1173-8804, pages 277 - 284, XP008185106 [X] 1,15 * abstract * * page 281, column 1, paragraph 2 * [Y] 1-16

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents